- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02139722
Patient-Centered Care and Asian Americans
A Patient-Centered Intervention to Increase Screening of Hepatitis B and C Among Asian Americans
Liver cancer and hepatitis B are health disparities for Asian Americans, and hepatitis C is a rising problem. Little is known about how to improve the quality of health care Asian Americans receive for viral hepatitis. Technology, specifically mobile applications, can provide a flexible and efficient way to address these challenges. This project seeks to develop, implement, and test an intervention to increase hepatitis B and C screening for Asian Americans in 2 healthcare systems in San Francisco.
The research team will develop, implement, and evaluate the efficacy of an interactive, patient- centered mobile app for use on a tablet computer to increase hepatitis B and C screening among unscreened Asian Americans age 18 and older. The team will use their experience in health promotion to develop the intervention by working with patients, community leaders and advocates, clinical staff, healthcare providers, and healthcare system administrators from a county safety net system and an academic primary care practice in the San Francisco Bay Area. The mobile application will include video clips with a physician (Video Doctor) addressing patient concerns regarding hepatitis B and C screening in the patient's preferred language, English, Chinese, or Vietnamese. A patient who has not been screened for hepatitis B will answer questions about his or her characteristics and preferences using the mobile application. The mobile application will then show 30-60 seconds video clips with messages that address the patient's responses related to hepatitis B screening and that are delivered by an actor playing a physician. Those who are born between 1945 and 1965 also receive messages about hepatitis C screening. At the end, the tablet computer will generate a provider alert to let the treating provider know what the patient's preferences are regarding testing for viral hepatitis.
Once developed, the intervention will then be used in combination with a physician panel notification and tested against physician panel notification only in a randomized controlled trial to see which approach is better in increasing the rate of hepatitis B and C screening. The team will also work with the 2 healthcare system to ensure that the interventions will be practical and easily adopted once the study is over. The findings of this project will greatly expand understanding about how to use technology- based interventions to improve quality of healthcare in diverse patient populations.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
California
-
San Francisco, California, Forente stater, 94143
- University of California, San Francisco
-
San Francisco, California, Forente stater, 94110
- Zuckerberg San Francisco General
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- ages 18+ years
- identifies as Asian
- Asian American, Chinese, or Vietnamese
- speaks English, Chinese (Cantonese), or Vietnamese
- does not have an electronic health record (EHR)-documented HBV screening test (defined as a hepatitis B surface antigen [HBsAg] test).
- we select Chinese and Vietnamese because those are the 2 most common languages spoken by limited English-proficient Asian Americans
Exclusion Criteria:
- dementia or any conditions precluding understanding informed consent or using a touch screen with audio
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Screening
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Ingen inngripen: Provider Panel Notification (PPN) Alone
The comparison procedures consist of a panel notification given to providers and an audio-visual presentation on diet and exercise given to patients.
|
|
Eksperimentell: Video Doctor, PA + PPN
Video Doctor (VD) and Provider Alert (PA) intervention combined with Provider Panel Notification (PPN)
|
The intervention consists of a Video Doctor and Provider Alert.
For the Video Doctor, we will develop a series of 30-60 seconds video clips, a branching algorithm, and a mobile application linking the baseline survey to the clips.
The Provider Alert is a point-of-care reminder printout generated by the mobile application to facilitate patient-provider communication.
The intervention integrates guidelines, literature, guidance from the Systems Model, our prior work, and input from patients and providers.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
EHR-documented hepatitis B surface antigen (HBsAg) test
Tidsramme: 3 months
|
The main outcome measure is an EHR-documented hepatitis B surface antigen (HBsAg) test at 3 months post-intervention.
We chose screening for hepatitis B because, among adults, particularly immigrants or descendants of immigrants, it is the most important first step in the control of viral hepatitis B and lack of screening remains a significant problem.
While many young adult Asian Americans born in the U.S. or who immigrated at a young age may have been vaccinated for hepatitis B as a child or prior to entering college, pre-vaccination testing may not have been done.
Given the high rates of infection in their parents and the possibility of vertical transmission, all Asian Americans should be tested for chronic hepatitis B using the HBsAg test.
All screening outcomes (test receipt) as well as test ordering by the healthcare providers will be collected from the medical record through the EHRs at 3-month post-intervention.
|
3 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Knowledge about hepatitis B virus (HBV) and hepatitis C virus (HCV)
Tidsramme: 3 months
|
Data sources include the self-administered pre-intervention survey via a tablet computer, and the post-intervention phone survey administered by a research assistant, and EHR.
All patient surveys will be done in the patient's preferred language (English, Chinese, or Vietnamese).
Pre- and post-intervention survey data of secondary outcomes include: Knowledge (awareness of HBV and HCV, screening test, modes of transmission); Self-efficacy (perceived confidence in initiating conversation and request screening test from providers); Patient-Provider Communication Experiences (asked provider for HBV or HCV test, discussed HBV or HCV test with provider, receipt of provider recommendation to get a HBV or HCV test).
|
3 months
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Tung T Nguyen, MD, University of California, San Francisco
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- RNA-virusinfeksjoner
- Virussykdommer
- Infeksjoner
- Blodbårne infeksjoner
- Smittsomme sykdommer
- Flaviviridae-infeksjoner
- Hepatitt, viral, menneskelig
- Hepadnaviridae-infeksjoner
- DNA-virusinfeksjoner
- Enterovirusinfeksjoner
- Picornaviridae-infeksjoner
- Leversykdommer
- Hepatitt B
- Hepatitt
- Hepatitt A-virus
- Hepatitt C
Andre studie-ID-numre
- AD-11-4615
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Hepatitt B
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeTilbakevendende diffust stort B-celle lymfom aktivert B-celletype | Refraktært diffust stort B-celle lymfom aktivert B-celletypeForente stater, Saudi-Arabia
-
Nathan DenlingerBristol-Myers SquibbRekrutteringB-celle non-Hodgkin lymfom - tilbakevendende | Diffust stort B-celle lymfom - tilbakevendende | Follikulært lymfom - tilbakevendende | Høygradig B-celle lymfom - tilbakevendende | Primært mediastinalt stort B-celle lymfom - tilbakevendende | Transformert indolent B-celle non-Hodgkin lymfom til... og andre forholdForente stater
-
British Columbia Cancer AgencyHar ikke rekruttert ennåB-celle lymfom | Non-Hodgkins lymfom | Mantelcellelymfom | Diffust storcellet B-celle lymfom | B-celle leukemi | B-celle akutt lymfatisk leukemi | Primært mediastinalt stort B-celle lymfom (PMBCL) | Høygradig B-celle lymfomCanada
-
Athenex, Inc.RekrutteringB-celle lymfom | CLL/SLL | ALT, barndom | DLBCL - Diffust storcellet B-celle lymfom | B-celle leukemi | NHL, tilbakefall, voksen | ALL, voksen B-celleForente stater
-
Lapo AlinariRekrutteringTilbakevendende høygradig B-celle lymfom med MYC-, BCL2- og BCL6-omorganiseringer | Refraktært høygradig B-celle lymfom med MYC, BCL2 og BCL6 omorganiseringer | Tilbakevendende høygradig B-celle lymfom med MYC og BCL2 eller BCL6 omorganiseringer | Refraktært høygradig B-celle lymfom med MYC... og andre forholdForente stater
-
Northwestern UniversityNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeDiffust stort B-celle lymfom | Diffust stort B-celle lymfom, ikke spesifisert på annen måte | Høygradig B-celle lymfom, ikke spesifisert på annen måte | T-celle/histiocytt-rik stort B-celle lymfom | Høygradig B-celle lymfom med MYC og BCL2 og/eller BCL6 omorganiseringer | Diffust stort B-celle... og andre forholdForente stater
-
Ohio State University Comprehensive Cancer CenterRekrutteringDiffust stort B-celle lymfom | Høygradig B-celle lymfom | Diffust stort B-celle lymfom, ikke spesifisert på annen måte | Diffust stort B-celle lymfom Germinalt senter B-celletypeForente stater
-
Curocell Inc.RekrutteringHøygradig B-celle lymfom | Diffust storcellet B-celle lymfom (DLBCL) | Primært mediastinalt stort B-celle lymfom (PMBCL) | Transformert follikulært lymfom (TFL) | Refraktært stort B-celle lymfom | Residiverende stort B-celle lymfomKorea, Republikken
-
University Hospital, CaenCNRS, UMR ISTCT 6301, LDM-TEP Groupe, GIP Cyceron, Caen, FranceFullførtUbehandlet B-kronisk lymfatisk leukemi eller diffus storcellet B-celle lymfompasienterFrankrike
-
National Cancer Institute (NCI)RekrutteringHøygradig B-celle lymfom | Diffust stort B-celle lymfom, ikke spesifisert på annen måte | Transformert indolent B-celle non-Hodgkin lymfom til diffust stort B-celle lymfomForente stater
Kliniske studier på Video Doctor, PA + PPN
-
NYU Langone HealthUnited States Department of DefenseFullført